Black Diamond Therapeutics, Inc. (BDTX) Aandelenanalyse

Bedrijfsoverzicht

Black Diamond Therapeutics, Inc. is a clinical-stage oncology enterprise dedicated to the discovery and development of MasterKey therapies tailored for patients with genetically defined tumors, with its primary focus currently centered on silevertinib, a brain-penetrant epidermal growth factor receptor inhibitor. Operating within the healthcare sector and specifically the biotechnology industry, the company targets a specialized niche where therapeutic agents are designed to address specific genetic mutations in tumors, distinguishing it from traditional broad-spectrum treatments. The firm currently employs 21 individuals and holds a market capitalization of $146.66M, reflecting its position as a mid-cap entity within the biotech landscape. With annual revenue recorded at $70.00M, these financial figures indicate a mature revenue stream for a company of this size, suggesting that the business has moved beyond the purest early-stage venture phase while maintaining a relatively compact operational footprint.

Financiële gezondheid

The company reports a trailing twelve-month revenue of $70.00M and generates a net income of $22.37M, resulting in an EBITDA of $20.20M. The significant difference between the $70.00M revenue and the $22.37M net income reveals a cost structure where operating expenses and taxes consume approximately 68% of gross sales, which is typical for biotechnology firms but warrants close monitoring. Black Diamond Therapeutics generates free cash flow of $13.03M, a metric that underscores substantial financial flexibility allowing for potential reinvestment in research and development or debt reduction without immediate external financing. The firm maintains robust profitability margins, with a gross margin of 100.0%, an operating margin of 28.4%, and a profit margin of 32.0%, indicating highly efficient production or sourcing relative to revenue generation. On the balance sheet, the company holds $128.65M in cash against $18.78M in debt, supported by a debt-to-equity ratio of 16.74, presenting a picture of a leveraged yet cash-rich entity. Liquidity is exceptionally strong, evidenced by a current ratio of 8.42, which signifies an ability to cover short-term obligations more than eight times over with current assets. Efficiency metrics show a return on equity of 22.9% and a return on assets of 9.3%, revealing that management is generating significant returns on shareholder capital relative to the asset base employed.

Waarderingsbeoordeling

Valuation multiples for Black Diamond Therapeutics, Inc. include a trailing P/E ratio of 6.56 and a forward P/E of -2.48, where the divergence between these figures implies an anticipated shift in earnings trajectory or a reclassification of future profitability expectations by the market. The price-to-book ratio stands at 1.30, suggesting that the market values the company at a modest premium over its net asset value, a common characteristic for biotech firms with valuable intellectual property. Alternative valuation metrics further illuminate the company's stance, with a price-to-sales ratio of 2.10 and an EV/EBITDA of 1.82, indicating that the stock is priced relative to its sales volume and earnings before interest, taxes, depreciation, and amortization at levels that may reflect high growth potential or specific industry risk premiums. Price momentum data shows a 52-week high of $4.94 and a 52-week low of $1.31, framing the current trading environment within this historical range. The beta of 3.39 indicates that the stock price is significantly more volatile than the broader market, moving with amplified intensity relative to general equity market fluctuations.

Growth & Income

The provided data indicates N/A for both revenue growth year-over-year and earnings growth year-over-year, meaning specific growth rates cannot be calculated from the current fiscal snapshot. Since the dividend yield is listed as N/A and the payout ratio is 0.0%, the company does not distribute cash to shareholders, which implies that all net income is retained and reinvested into the business for future expansion rather than being paid out. This retention policy is consistent with the capital-intensive nature of the biotechnology sector, where companies prioritize funding clinical trials and drug development over immediate income distribution. Consequently, the overall growth and income profile is characterized by zero current dividend income and a reliance on internal capital generation and market valuation appreciation rather than yield or reported growth rates in this specific reporting period.